MarginsXMarginsX
Home › Markets › Health Care › LFVN

Lifevantage Corporation Common Stock (Delaware) (LFVN)

LFVN trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$4.77
-4.02% on the day
Market cap
$60.5M
Micro cap
Revenue · 2026
$182.6M
-20.1% on 2025
Net income · 2026
$5.1M
2.8% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2026-06-30, https://www.sec.gov/Archives/edgar/data/849146/000119312526371257/0001193125-26-371257-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2026-06-30.

Profile

FieldValue
TickerLFVN on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO yearNot reported by the screener
SEC CIK0000849146
SEC industry codePharmaceutical Preparations
Incorporated inCOLORADO

Financials · 2026

LineValue
Revenue$182.6M
Net income$5.1M
Operating income$6.1M
Net margin2.8%
Operating margin3.3%
Revenue growth-20.1%
Cash$14.9M
Total assets$62.1M
P/E (computed)11.9×
P/S (computed)0.3×

Warning signs

Cash runway
Cash-flow positive
$13.7M cash at September 30, 2026
Share count, 1 year
-0.1%
2025-11-03 to 2026-11-06 · -0.2% over 3 years
Going-concern doubt
No
10-Q filed November 9, 2026
Insider net buying, 12 months
-$276K
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-09
Cash and burn$13.7M cash; operating cash flow $3.3M a quarter.Report 2026-09-30
Shares outstanding12,682,221 (2026-11-06); 12,701,187 a year earlier; 12,713,887 three years earlier.Cover page 2026-11-06
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 0 424B5 takedownsLatest 2026-03-10
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorDeloitte & Touche LLP, Salt Lake City, Utah, United StatesPCAOB Form AP 2026-09-04
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $196K, sold $472K on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q1 2027
2026-09-30
$37.1M-$196K$533K$13.7MNo debt tags$172.1M10-Q 2026-11-09
Q4 2026
2026-06-30
$42.4M$1.3M$4.8M$14.9MNo debt tags$182.6M10-K 2026-08-27
Q3 2026
2026-03-31
$43.7M$1.4M$5.0M$12.5MNo debt tags$195.3M10-Q 2026-05-06
Q2 2026
2025-12-31
$48.9M$276K$2.8M$10.2MNo debt tags$210.0M10-Q 2026-02-04
Q1 2026
2025-09-30
$47.6M$2.2M-$2.3M$13.1MNo debt tags$228.9M10-Q 2026-11-09
Q4 2025
2025-06-30
$55.1M$2.0M$1.0M$20.2MNo debt tags$228.5M10-K 2026-08-27
Q3 2025
2025-03-31
$58.4M$3.5M$2.2M$22.5MNo debt tags$222.3M10-Q 2026-05-06
Q2 2025
2024-12-31
$67.8M$2.5M$9.2M$21.6MNo debt tags$212.2M10-Q 2026-02-04

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering documentS-32026-03-10
Latest annual report10-K2026-08-27
Latest quarterly / interim10-Q2026-11-09
Latest current report8-K2026-11-12
Latest proxyDEFA14A2026-09-18

Source: SEC EDGAR submissions feed, 1,002 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-4.8%
1 month-16.5%
3 months-23.4%
Year to date-19.3%
1 year-23.2%
From 52-week high-53.6%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
MAIAMAIA Biotechnology Inc.$1.01+1.00%$62.4M
ACRVAcrivon Therapeutics Inc.$1.46+0.69%$62.6M
FBIOFortress Biotech Inc.$1.71-9.04%$57.7M
BOLDBoundless Bio Inc.$2.41-3.60%$56.9M
XBITXBiotech Inc.$1.85-5.37%$56.4M
TNXPTonix Pharmaceuticals Holding Corp.$2.88-4.32%$56.0M
SPROSpero Therapeutics Inc.$0.9464-5.35%$55.1M
VRCAVerrica Pharmaceuticals Inc.$3.20-10.11%$55.0M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier